Prophylaxis vs. on-demand treatment with Nuwiq® (Human-cl rhFVIII) in adults with severe haemophilia A

Haemophilia

Volumn 22, Issue 3, 2016, Pages 374-380

  Tiede, A ^a   Oldenburg, J ^b   Lissitchkov, T ^c   Knaub, S ^d   Bichler, J ^d   Manco Johnson, M J ^e  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c Specialised Hospital for Active Treatment Joan Pavel   (Bulgaria)

^d Octapharma AG   (Switzerland)

^e Mountain States Regional Hemophilia and Thrombosis Center   (United States)

Author keywords

Haemophilia A; Human cl rhFVIII; Nuwiq; On demand; Prophylaxis; PTPs

Indexed keywords

BLOOD CLOTTING FACTOR 8 INHIBITOR; RECOMBINANT BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8; COAGULATING AGENT; RECOMBINANT PROTEIN;

ADOLESCENT; ADULT; AGED; ANNUALIZED BLEEDING RATE; ARTICLE; BLEEDING; CHILD; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG USE; EFFICACY PARAMETERS; HEMARTHROSIS; HEMOPHILIA A; HUMAN; IMMUNOGENICITY; INJECTION SITE INFLAMMATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY (TOPIC); OPEN STUDY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROPHYLAXIS; RECURRENT DISEASE; SIDE EFFECT; SPONTANEOUS BLEEDING; TRAUMATIC BLEEDING; BIOSYNTHESIS; CLINICAL TRIAL; DRUG ADMINISTRATION; GENETICS; HEMORRHAGE; MALE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHILD; COAGULANTS; DRUG ADMINISTRATION SCHEDULE; FACTOR VIII; HEMOPHILIA A; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84947575330     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12859     Document Type: Article

References (30)

1. Franchini M. The modern treatment of haemophilia: a narrative review. Blood Transfus 2013; 11: 178-82.
2. White GC, Rosendaal F, Aledort LM et al. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001; 85: 560.
3. Coppola A, Di CM, Di Minno MN et al. Treatment of hemophilia: a review of current advances and ongoing issues. J Blood Med 2010; 1: 183-95.
4. Makris M. Prophylaxis in haemophilia should be life-long. Blood Transfus 2012; 10: 165-8.
5. Srivastava A, Brewer AK, Mauser-Bunschoten EP et al. Guidelines for the management of hemophilia. Haemophilia 2013; 19: e1-47.
6. Manco-Johnson MJ, Abshire TC, Shapiro AD et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-44.
7. Gringeri A, Lundin B, Von MS et al. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost 2011; 9: 700-10.
8. Tagliaferri A, Franchini M, Coppola A et al. Effects of secondary prophylaxis started in adolescent and adult haemophiliacs. Haemophilia 2008; 14: 945-51.
9. Noone D, O'Mahony B, van Dijk JP et al. A survey of the outcome of prophylaxis, on-demand treatment or combined treatment in 18-35-year old men with severe haemophilia in six countries. Haemophilia 2013; 19: 44-50.
10. Collins P, Faradji A, Morfini M et al. Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study. J Thromb Haemost 2010; 8: 83-9.
11. Aznar JA, Garcia-Dasi M, Perez-Alenda S et al. Secondary prophylaxis vs. on-demand treatment to improve quality of life in severe adult haemophilia A patients: a prospective study in a single centre. Vox Sang 2014; 106: 68-74.
12. Manco-Johnson MJ, Kempton CL, Reding MT et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). J Thromb Haemost 2013; 11: 1119-27. Corrigendum: J Thromb Haemost 2013, 12: 119-122.
13. Casademunt E, Martinelle K, Jernberg M et al. The first recombinant human coagulation factor VIII of human origin: human cell line and manufacturing characteristics. Eur J Haematol 2012; 89: 165-76.
14. Kannicht C, Ramstrom M, Kohla G et al. Characterisation of the post-translational modifications of a novel, human cell line-derived recombinant human factor VIII. Thromb Res 2012; 131: 78-88.
15. Sandberg H, Kannicht C, Stenlund P et al. Functional characteristics of the novel, human-derived recombinant FVIII protein product, human-cl rhFVIII. Thromb Res 2012; 130: 808-17.
16. Hokke CH, Bergwerff AA, van Dedem GWK et al. Sialylated carbohydrate chains of recombinant human glycoproteins expressed in Chinese hamster ovary cells contain traces of N-glycolylneuraminic acid. FEBS 1990; 275: 9-14.
17. Hironaka T, Furukawa K, Esmon PC et al. Comparative study of the sugar chains of factor VIII purified from human plasma and from the culture media of recombinant baby hamster kidney cells. J Biol Chem 1992; 267: 8012-20.
18. ®) in adults with severe haemophilia A: efficacy and safety. Haemophilia 2015; Aug 28. doi: 10.1111/hae.12793. [Epub ahead of print].
19. Feldman BM, Funk SM, Bergstrom BM et al. Validation of a new pediatric joint scoring system from the International Hemophilia Prophylaxis Study Group: validity of the hemophilia joint health score. Arthritis Care Res (Hoboken) 2011; 63: 223-30.
20. Verbruggen B, Novakova I, Wessels H et al. The Nijmegen modification of the Bethesda assay for factor VIII: C inhibitors: improved specificity and reliability. Thromb Haemost 1995; 73: 247-51.
21. Manco-Johnson MJ, Kempton CL, Reding MT et al. 3-year results from SPINART: prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII. Presented as an abstract presentation at the World Federation of Hemophilia, 2014 Congress, May 2014.
22. Lundin B, Hong W, Raunig D et al. Effect on joint health of routine prophylaxis with Bayer's sucrose-formulated recombinant factor VIII (rFVIII-FS) in adolescents and adults previously treated on demand: MRI analyses from the 3-year SPINART study. Poster presentation to the ASH, San Francisco, CA, December 7, 2014; Abstr #2854.
23. Farrugia A, Cassar J, Kimber MC et al. Treatment for life for severe haemophilia A - A cost-utility model for prophylaxis vs. on-demand treatment. Haemophilia 2013; 19: e228-38.
24. Klamroth R, Lissitchkov T, Ruben L et al. Personalized prophylaxis with human-cl rhFVIII in hemophilia A patients. J Thromb Haemost 2015; 13(Suppl. 2): 850, P0272-WED.
25. Valentino LA, Negrier C, Kohla G et al. The first recombinant FVIII produced in human cells - an update on its clinical development programme. Haemophilia 2014; 20(Suppl. 1): 1-9.
26. Brown TM, Lee WC, Joshi AV et al. Health-related quality of life and productivity impact in haemophilia patients with inhibitors. Haemophilia 2009; 15: 911-17.
27. Darby SC, Keeling DM, Spooner RJ et al. The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99. J Thromb Haemost 2004; 2: 1047-54.
28. Morfini M, Haya S, Tagariello G et al. European study on orthopaedic status of haemophilia patients with inhibitors. Haemophilia 2007; 13: 606-12.
29. Gringeri A, Mantovani LG, Scalone L et al. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003; 102: 2358-63.
30. Hilliard P, Funk S, Zourikian N et al. Hemophilia joint health score reliability study. Haemophilia 2006; 12: 518-25.